These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Clark M; Colombel JF; Feagan BC; Fedorak RN; Hanauer SB; Kamm MA; Mayer L; Regueiro C; Rutgeerts P; Sandborn WJ; Sands BE; Schreiber S; Targan S; Travis S; Vermeire S Gastroenterology; 2007 Jul; 133(1):312-39. PubMed ID: 17631151 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic Drug Monitoring in IBD: Prospective Promise Unfulfilled. Govani SM; Waljee AK Am J Gastroenterol; 2017 May; 112(5):670-672. PubMed ID: 28323274 [No Abstract] [Full Text] [Related]
7. Translating inflammatory bowel disease research into clinical medicine. Neurath MF; Finotto S Immunity; 2009 Sep; 31(3):357-61. PubMed ID: 19766078 [TBL] [Abstract][Full Text] [Related]
8. How to manage the logistics of biological therapy. Headon B J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():42. PubMed ID: 26990005 [No Abstract] [Full Text] [Related]
9. Prevalence of Covid-19 Symptoms Among Inflammatory Bowel Disease Patients Treated with Biological Agents. Conley TE; Probert C; Subramanian S J Crohns Colitis; 2020 Dec; 14(12):1794-1795. PubMed ID: 32918090 [No Abstract] [Full Text] [Related]
10. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Sokol H; Beaugerie L Gut; 2009 Oct; 58(10):1427-36. PubMed ID: 19749141 [TBL] [Abstract][Full Text] [Related]
11. Risks and benefits of biologic therapy for IBD. Hommes DW J Pediatr Gastroenterol Nutr; 2009 Apr; 48 Suppl 2():S52-3. PubMed ID: 19300125 [No Abstract] [Full Text] [Related]
12. Optimizing the benefit to risk ratio of medical therapy of inflammatory bowel diseases. Van Assche G Verh K Acad Geneeskd Belg; 2008; 70(5-6):339-46. PubMed ID: 19725393 [TBL] [Abstract][Full Text] [Related]
13. [Systemic corticosteroids in inflammatory bowel disease: are they really effective. What is their real toxicity?]. Bastida G; Muñoz F Gastroenterol Hepatol; 2008 Sep; 31 Suppl 3():3-9. PubMed ID: 19087857 [No Abstract] [Full Text] [Related]
14. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease. Kanai T; Nemoto Y; Kamada N; Totsuka T; Hisamatsu T; Watanabe M; Hibi T Curr Opin Gastroenterol; 2009 Jul; 25(4):306-13. PubMed ID: 19448533 [TBL] [Abstract][Full Text] [Related]
15. How to achieve deep remission in treatment of inflammatory bowel disease. Han J; Wang J; Wang JH J Tradit Chin Med; 2013 Aug; 33(4):549-52. PubMed ID: 24187881 [TBL] [Abstract][Full Text] [Related]
16. Parvovirus B19 infection and immunosuppressed IBD-affected pediatricians. Montanari M; Cortelezzi C; Parravicini M; Gianfrate L; Piana S; Segato S Am J Gastroenterol; 2009 Feb; 104(2):537. PubMed ID: 19174790 [No Abstract] [Full Text] [Related]
18. Are we ready for top-down therapy for inflammatory bowel diseases: pro. van der Woude CJ; Hommes DW Expert Rev Gastroenterol Hepatol; 2007 Dec; 1(2):243-8. PubMed ID: 19072416 [TBL] [Abstract][Full Text] [Related]
19. [Locally acting corticosteroids in inflammatory bowel disease. Are they effective? Are they really less toxic?]. Nos Mateu P Gastroenterol Hepatol; 2008 Sep; 31 Suppl 3():16-21. PubMed ID: 19087859 [No Abstract] [Full Text] [Related]
20. Medical therapy of IBD in 2009. Harris A; Feller ER; Shah SA Med Health R I; 2009 Mar; 92(3):78-81. PubMed ID: 19385382 [No Abstract] [Full Text] [Related] [Next] [New Search]